Education
About Us
Working with TipRanks
Follow Us
Benitec Biopharma Ltd (BNTC)
NASDAQ:BNTC
BNTC Stock Chart & Stats
$12.30
<$0.01(0.09%)
At close: 4:00 PM EST
$12.30
<$0.01(0.09%)
Day’s Range― - ―
52-Week Range$9.70 - $17.15
Previous CloseN/A
Volume10.71K
Average Volume (3M)223.97K
Market Cap
$411.09M
Enterprise Value$488.77M
Total Cash (Recent Filing)$94.48M
Total Debt (Recent Filing)$817.00K
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Feb 16, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding33,862,225
10 Day Avg. Volume179,178
30 Day Avg. Volume223,973
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)4.35
Price to Sales (P/S)0.00
P/FCF Ratio-17.95
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue879.08
Enterprise Value/Gross Profit5.37K
Enterprise Value/Ebitda-9.99
Forecast
1Y Price Target
$27.00Price Target Upside119.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.27
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial EfficacyEarly BB-301 patients met predefined responder criteria and reported meaningful improvements in swallowing, indicating potential for durable clinical benefit that could drive adoption if confirmed.
Financing And Cash RunwayA substantial recent equity raise materially strengthened the balance sheet and should fund continued BB-301 development, reducing near-term financing risk.
Regulatory PathwayFast track and orphan disease designations, together with proactive regulator engagement, support a more streamlined route toward a pivotal study and potential accelerated approval.
Bears Say
Data Robustness RiskPositive findings come from a small patient group, so confirmatory results will be necessary to validate efficacy and could expose the program to higher clinical risk.
Dilution And Valuation PressureEquity dilution from the recent financing prompted downward pressure on the price target and may weigh on per-share valuation until clinical milestones are achieved.
Operating Losses And Cash BurnOngoing reported net losses underscore continued cash burn from trial activities and increase sensitivity to cost overruns or delays before revenue-generating events occur.
Benitec Biopharma News
BNTC FAQ
What was Benitec Biopharma Ltd’s price range in the past 12 months?
Benitec Biopharma Ltd lowest stock price was $9.70 and its highest was $17.15 in the past 12 months.
What is Benitec Biopharma Ltd’s market cap?
Benitec Biopharma Ltd’s market cap is $411.09M.
When is Benitec Biopharma Ltd’s upcoming earnings report date?
Benitec Biopharma Ltd’s upcoming earnings report date is Feb 16, 2026 which is in 31 days.
How were Benitec Biopharma Ltd’s earnings last quarter?
Benitec Biopharma Ltd released its earnings results on Nov 14, 2025. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.45 by $0.23.
Is Benitec Biopharma Ltd overvalued?
According to Wall Street analysts Benitec Biopharma Ltd’s price is currently Undervalued.
Does Benitec Biopharma Ltd pay dividends?
Benitec Biopharma Ltd pays a Notavailable dividend of $0.765 which represents an annual dividend yield of N/A. See more information on Benitec Biopharma Ltd dividends here
What is Benitec Biopharma Ltd’s EPS estimate?
Benitec Biopharma Ltd’s EPS estimate is -0.22.
How many shares outstanding does Benitec Biopharma Ltd have?
Benitec Biopharma Ltd has 33,862,225 shares outstanding.
What happened to Benitec Biopharma Ltd’s price movement after its last earnings report?
Benitec Biopharma Ltd reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.45. Following the earnings report the stock price went up 2.812%.
Which hedge fund is a major shareholder of Benitec Biopharma Ltd?
Currently, no hedge funds are holding shares in BNTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Benitec Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.00 (119.51% Upside)
$27.00 (119.51% Upside)
Blogger Sentiment
Bullish
BNTC Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $22.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.7%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.38%
12-Months-Change
Fundamentals
Return on Equity
-43.71%
Trailing 12-Months
Asset Growth
39.63%
Trailing 12-Months
Company Description
Benitec Biopharma Ltd
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
BNTC Stock 12 Month Forecast
Average Price Target
$27.00
▲(119.51% Upside)
Technical Analysis
Tvardi Therapeutics
―
Assembly Biosciences
―
Rocket Pharmaceuticals
―
4D Molecular Therapeutics
―
Aura Biosciences Inc
―
Ownership Overview
5.76% Insiders
7.21% Mutual Funds
41.27% Other Institutional Investors
40.64% Public Companies and
Individual Investors